Oxidative stress, caused by free radicals, is a significant factor in aging and cellular damage
The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
It measures how much of the material is the target peptide versus impurities
The patients using both tend to be longevity-focused, productivity-oriented, and proactive about aging rather than reactive
With its ability to boost metabolism, increase energy, and preserve muscle, its quickly becoming one of the most talked-about fat loss peptides in modern integrative medicine